BioCentury
ARTICLE | Clinical News

Imfinzi fails again in MYSTIC trial for first-line NSCLC

November 30, 2018 6:35 PM UTC

In another strike against tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the co-primary endpoint of improving overall survival (OS) in the Phase III MYSTIC trial to treat previously untreated non-small cell lung cancer.

AZ leadership had called OS a more clinically meaningful endpoint than progression-free survival (PFS) after the combo missed the PFS endpoint in 2017 (see "AZ Plummets on MYSTIC Readout in NSCLC")...